MiMedx Q1 Sales Miss Estimates, Full-Year Outlook Cut Amid Reimbursement Challenges
Summary
MiMedx Group reported first-quarter sales of $58.991 million, falling significantly short of the IBES estimate of $65 million. The company also provided a full-year sales outlook of $260-290 million, which is below the analyst consensus of $307 million, alongside reporting an operating loss and net loss for the quarter. This performance confirms the negative impact of Medicare reimbursement cuts for skin substitutes, a risk the company had previously highlighted in its February 2026 10-K filing and which analysts had anticipated in a Reuters report on April 27, 2026. The substantial sales miss and lowered full-year guidance are material negative developments, indicating that the company's challenges are persisting despite a recent cost reduction plan initiated in mid-April. Traders will be closely monitoring management's strategies to navigate these reimbursement pressures and restore sales growth.
At the time of this announcement, MDXG was trading at $3.07 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $458.3M. The 52-week trading range was $3.03 to $7.99. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: Reuters.